Synaptogenix (TAOX) Competitors

Synaptogenix's return on equity of -193.08% beat Cardiol Therapeutics' return on equity.

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Cardiol Therapeutics has higher earnings, but lower revenue than Synaptogenix. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Cardiol Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 548.85%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Synaptogenix.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 430.29%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Synaptogenix.

Tenaya Therapeutics' return on equity of -85.20% beat Synaptogenix's return on equity.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for Synaptogenix. Tenaya Therapeutics' average media sentiment score of 0.51 beat Synaptogenix's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Synaptogenix has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500.

In the previous week, InflaRx had 8 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for InflaRx and 0 mentions for Synaptogenix. InflaRx's average media sentiment score of 0.56 beat Synaptogenix's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.

InflaRx's return on equity of -80.51% beat Synaptogenix's return on equity.

InflaRx has a consensus price target of $5.80, indicating a potential upside of 194.42%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Synaptogenix.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Synaptogenix has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.

In the previous week, Galectin Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Galectin Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Galectin Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 393.27%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Synaptogenix.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Synaptogenix has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Galectin Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.